hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06357286 id: IRB0148156 briefTitle: Income Volatility and Mental Health, Pilot Study overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-09-10 date: 2024-10-10 date: 2024-04-10 date: 2024-04-10 name: Cornell University class: OTHER briefSummary: Income instability is a defining aspect of the lives of the poor, who also disproportionately suffer from poor mental and physical health. Our research is the first to assess the causal effects of predictable and unpredictable income instability on the psychological and physical health of the poor. It will advance the scientific knowledge on the effects of economic instability as well as our understanding of health disparities. conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 400 type: ESTIMATED name: Work opportunities measure: Depression sex: FEMALE minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357273 id: WhiteTeaAY briefTitle: The Effect of White Tea Consumption on Obesity overallStatus: COMPLETED date: 2023-07-01 date: 2023-11-01 date: 2023-12-15 date: 2024-04-10 date: 2024-04-10 name: Recep Tayyip Erdogan University class: OTHER briefSummary: Obesity is an increasing global public health issue. In general, tea consumption have been shown to offer benefit to obese patients. However, the potential of white tea (WT) to treat and protect from the adverse effects of obesity have not been addressed so far. The aim of this study was to examine the efficacy and impact WT consumption highest in catechins on levels of anthropometric and biochemical values in obese patients. conditions: Obesity conditions: Obesity; Endocrine conditions: Obesity Adult Onset studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 91 type: ACTUAL measure: Weight loss measure: Waist Circumference measure: Body Mass Index measure: Tumor Necrosis Factor - alpha measure: Total cholesterol measure: Low-Density Lipoprotein cholesterol measure: High-Density Lipoprotein cholesterol sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Recep Tayyip Erdogan University city: Rize zip: 53100 country: Turkey lat: 41.02083 lon: 40.52194 hasResults: False
nctId: NCT06357260 id: Shifa OMR briefTitle: Pregabalin as an add-on Therapy to Carbamazepine in Trigeminal Neuralgia Patients overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-02 date: 2025-03 date: 2024-04-10 date: 2024-04-10 name: Postgraduate Institute of Dental Sciences Rohtak class: OTHER briefSummary: Trigeminal neuralgia is a very painful condition associated with paroxysmal severe episodes of pain. Carbamazepine has been the first line of drug for Trigeminal Neuralgia. However, there are several adverse effects linked with Carbamazepine like drowsiness, accommodation disorders, hepatitis, derangement in hepatic enzymes, renal dysfunction. Pregabalin which is an established drug in neuropathic pain has better pharmacokinetic nature which allows for easy management and rapid dose escalation to therapeutic doses. There have been only few trials evaluating efficacy of Pregabalin in classical trigeminal neuralgia. Thus, the present study is designed to evaluate the efficacy of Pregabalin as an add-on therapy to carbamazepine in patients suffering from Trigeminal Neuralgia. In present trial 50 patients fulfilling the exclusion and inclusion criteria will be recruited in two arms that is test group and the control group. The test group will be prescribed carbamazepine along with fixed dose of Pregabalin 75mg twice daily while the control group will be prescribed carbamazepine only. The dose of carbamazepine will be titrated in both groups as per patients need. The outcome regarding pain relief, quality of life and adverse effects and mean dose of carbamazepine required in both groups will be evaluated. conditions: Trigeminal Neuralgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Test group-1 will be administered carbamazepine+pregabalin with fixed dose of pregabalin 75mg BD and carbamazepine being titrated as per patients's need and follow up done after 1 week with subsequent follow up at 2,4,6 and 8 weeks.
control group all the armamentarium and procedure will remain same except that dose titration of carbamazepine is done till patient is relieved of pain. primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Pregabalin and Carbamazepine name: Carbamazepine measure: VAS score measure: Brief pain inventory ● Brief pain inventory assessment of pain. ● Brief pain inventory assessment of pain. Brief pain inventory measure: Patient Global Impression of change(PGI) measure: mean dose of carbamazepine measure: Liverpool scale sex: ALL minimumAge: 25 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: PGIDS city: Rohtak state: Haryana zip: 124001 country: India name: DR. Lavina Arya, MDS role: CONTACT phone: 09212795285 email: aryalavina@gmail.com name: Dr. Ambika Gupta, MDS role: CONTACT phone: 09315903300 email: drambika79@rediffmail.com name: Shifa Akhtar, MDS role: PRINCIPAL_INVESTIGATOR lat: 28.89447 lon: 76.58917 hasResults: False
nctId: NCT06357247 id: HM20027093 briefTitle: The Effect of SRS on Hemiplegia in Stroke Survivors overallStatus: RECRUITING date: 2024-03-04 date: 2024-08 date: 2024-08 date: 2024-04-10 date: 2024-04-10 name: Virginia Commonwealth University class: OTHER briefSummary: Strokes are one of the leading causes of long term disability and death in the United States. A stroke occurs when the blood supply to the brain is blocked, damaging parts of the brain. Many stroke survivors have difficulty completing dexterous hand movements and manipulating objects due brain damage in the sensorimotor cortex. Damage to these areas can cause decreased motor movements and tactile sensation on the affected side. Research shows that tactile sensation is necessary for maintaining grip, grading grip forces and decreasing object slippage. Therefore, it is important to address tactile sensation with motor performance during stroke rehabilitation to improve performance outcomes among stroke survivors. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 20 type: ESTIMATED name: Sensory Threshold name: Nine Hole Peg Test name: Semmes Weinstein Monofilament Assessment measure: Scores on ease of use, duration of wear, and preference related to wearing a stochastic resonance device at home in chronic stroke patients measure: Optimal level of stochastic resonance vibration sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Virginia Commonwealth University status: RECRUITING city: Richmond state: Virginia zip: 232398 country: United States name: Virginia Chu role: CONTACT phone: 804-828-1564 email: vchu@vcu.edu lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06357234 id: APRE-2023 briefTitle: Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-03 date: 2026-04 date: 2024-04-10 date: 2024-04-10 name: IWK Health Centre class: OTHER briefSummary: This research trial will measure how useful Aprepitant is in preventing nausea and vomiting in children having surgery to correct scoliosis (curvature of the spine). conditions: Spinal Fusion conditions: Nausea and Vomiting, Postoperative conditions: Anesthesia studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a randomized double-blind placebo controlled study primaryPurpose: PREVENTION masking: QUADRUPLE maskingDescription: Treatment arm of participants will be masked until data collection is complete. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Aprepitant name: Placebo measure: Anti-Nausea Rescue Medication measure: Anti-nausea rescue medication administered by post-operative day measure: Emesis (Yes/No) measure: Baxter Retching Faces score measure: Pain score measure: Headache (yes/no) measure: Flatus (yes/no) measure: Bowel Motility (yes/no) measure: Sensation of Itch measure: Treatment of emergent adverse events sex: ALL minimumAge: 8 Years maximumAge: 19 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06357221 id: GLI.04.US.SL.035 briefTitle: A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients overallStatus: RECRUITING date: 2024-04-08 date: 2024-07-31 date: 2024-07-31 date: 2024-04-10 date: 2024-04-10 name: Galderma R&D class: INDUSTRY briefSummary: Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline. conditions: Plaque Psoriasis conditions: Psoriasis studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Cetaphil measure: Change in psoriatic Body Surface Area compared to baseline measure: Change in target lesion severity compared to baseline measure: Change of Physician Global Assessment compared to baseline measure: Change in skin quality measured by macroscopic imaging measure: Subject treatment satisfaction measure: Incidence of psoratic irritation [tolerability assessment] measure: Subject Quality of Life Satisfaction sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Southeast Dermatology Specialists, LLC status: NOT_YET_RECRUITING city: Columbus state: Georgia zip: 31904 country: United States name: George F Hougeir, MD role: CONTACT phone: 706-568-2700 email: hougeir@gmail.com name: Moriah Hibbard role: CONTACT email: mhibbard@sedsderm.com name: George F Hougeir, MD role: PRINCIPAL_INVESTIGATOR lat: 32.46098 lon: -84.98771 facility: Southeast Dermatology Specialists, LLC status: NOT_YET_RECRUITING city: Douglasville state: Georgia zip: 30135 country: United States name: George F Hougeir, MD role: CONTACT phone: 678-702-3376 email: hougeir@gmail.com name: Moriah Hibbard role: CONTACT email: mhibbard@sedsderm.com name: George F Hougeir, MD role: PRINCIPAL_INVESTIGATOR lat: 33.7515 lon: -84.74771 facility: Dermatology Consulting Services status: RECRUITING city: High Point state: North Carolina zip: 27262 country: United States name: Zoe D Draelos, MD role: CONTACT phone: 336-841-2040 email: zdraelos@northstate.net name: Crystal Williams role: CONTACT email: dcs11@northstate.net name: Zoe D Draelos, MD role: PRINCIPAL_INVESTIGATOR lat: 35.95569 lon: -80.00532 hasResults: False
nctId: NCT06357208 id: 23-AOI-06 id: 2023-A02687-38 type: OTHER domain: ANSM briefTitle: IMPACT OF BREATH CONTROL AND RETENTION ON PATIENT STRESS. E.S IN MEDICALLY ASSISTED REPRODUCTION BREATH HOLD TO BREATH BETTER PROGRAM acronym: BHBB overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-06-01 date: 2025-12-01 date: 2024-04-10 date: 2024-04-10 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: we propose for patient in the course of Medically Assisted Reproduction a study with to arm: one arm active "Breathing Control and Retention" and the other arm control conditions: Reproductive Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 30 type: ESTIMATED name: Breathing Control and Retention measure: Rate of stressed patients measure: STAI Y-A (anxiety state) scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chu de Nice city: Nice zip: 06003 country: France name: Valérie BENOIT role: CONTACT phone: 0492034702 email: benoit.v@chu-nice.fr name: marion causeret role: CONTACT phone: 0492034702 email: causeret.m@chu-nice.fr name: Valérie BENOIT role: PRINCIPAL_INVESTIGATOR lat: 43.70313 lon: 7.26608 hasResults: False
nctId: NCT06357195 id: 2024H0075 briefTitle: DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2024-10-01 date: 2024-10-01 date: 2024-04-10 date: 2024-04-10 name: Ohio State University class: OTHER briefSummary: The goal of this observational study is to learn about current practices for the acute neuropsychiatric management of older adults during emergency department (ED) visits. Researchers will compare current standard of care practices with implemented guideline practice to see if standardized medication guidelines help reduce the usage of antipsychotics and/or benzodiazepines during acute presentations. The main questions this study aims to answer are:
* Does implementation of standardized medication guidelines help reduce the usage of antipsychotics and/or benzodiazepines during acute presentations? conditions: Emergency Psychiatric conditions: Cognition Disorder conditions: Movement Disorders conditions: Antipsychotics and Neuroleptics Toxicity conditions: Dementia With Lewy Bodies conditions: Alteration in Mental Status conditions: Behavior conditions: Aging studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 1000 type: ESTIMATED measure: Antipsychotic/Benzodiazepine measure: Clinical Indication measure: Length of Stay measure: Disposition measure: Code Status sex: ALL minimumAge: 54 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357182 id: STUDY00026136 id: NCI-2024-01262 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: STUDY00026136 type: OTHER domain: OHSU Knight Cancer Institute briefTitle: Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia overallStatus: NOT_YET_RECRUITING date: 2024-05-08 date: 2026-03-08 date: 2026-05-29 date: 2024-04-10 date: 2024-04-10 name: OHSU Knight Cancer Institute class: OTHER name: Oregon Health and Science University name: Oryzon Genomics S.A. briefSummary: This phase I trial tests the safety, side effects, and best dose of iadademstat when given together with azacitidine and venetoclax in treating patients with newly diagnosed acute myeloid leukemia (AML). Iadademstat inhibits the LSD1 protein and may lead to inhibition of cell growth in LSD1-overexpressing cancer cells. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving iadademstat with azacitidine and venetoclax may be safe, tolerable and/or effective in treating patients with newly diagnosed AML who cannot undergo intensive chemotherapy. conditions: Acute Myeloid Leukemia conditions: Myelodysplastic Syndrome/Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: The treatment plan starts with a 7 day monotherapy lead-in (Cycle 0 \[C0\]) and then proceeds to combination therapy in 28 day cycles. Disease will be assessed pre-treatment (Screening/Baseline), at the end of monotherapy, in C1 (and C2, if response is not observed in C1), and at the end of alternating cycles, thereafter. A disease assessment will also be conducted within 30 days of the last dose of IADA. Participants that do not achieve response after up to 2 cycles of the triplet regimen will be taken off treatment. primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Azacitidine name: Biospecimen Collection name: Bone Marrow Biopsy name: Echocardiography name: Iadademstat name: Multigated Acquisition Scan name: Questionnaire Administration name: Venetoclax measure: Incidence of dose-limiting toxicities (DLTs) within specific iadademstat (IADA) dose levels measure: Percentage of efficacy-evaluable participants achieving composite complete remission (cCR) measure: Percentage of efficacy-evaluable participants achieving an overall response (ORR) measure: Incidence of treatment-emergent grade ≥ 3 adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: OHSU Knight Cancer Institute city: Portland state: Oregon zip: 97239 country: United States name: Curtis A. Lachowiez role: CONTACT phone: 503-494-5058 email: lachowie@ohsu.edu name: Curtis A. Lachowiez role: PRINCIPAL_INVESTIGATOR lat: 45.52345 lon: -122.67621 hasResults: False
nctId: NCT06357169 id: Venus Glow briefTitle: Mechanical Intervention on the Scalp Microbiome: Setting the Stage for the Future Management of Cicatricial Alopecias overallStatus: COMPLETED date: 2023-01-13 date: 2023-06-30 date: 2024-01-13 date: 2024-04-10 date: 2024-04-10 name: University of Minnesota class: OTHER briefSummary: The objective of this study is to assess the effect of standardized scalp care, specifically mechanical cleansing with the Venus Glow™ Device and water, on the scalp microbiome. This study also seeks to characterize the microbiome of the normal, healthy scalp, thereby providing a baseline for which the scalp affected by hair and scalp disease can be compared. conditions: Lichen Planopilaris of Scalp conditions: Alopecia Areata studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ACTUAL name: Venus Glow measure: scalp microbiome composition measure: scalp health sex: ALL minimumAge: 18 Years maximumAge: 35 Years stdAges: ADULT facility: University of Minnesota city: Minneapolis state: Minnesota zip: 55455 country: United States lat: 44.97997 lon: -93.26384 hasResults: False
nctId: NCT06357156 id: ORAD-621 briefTitle: Evaluating the Topographic and Quantitative Differences of the Mandibular Symphysis Area Between Males and Females Egyptians Using CBCT Scans: a Cross-sectional Study overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-01-30 date: 2025-03-30 date: 2024-04-10 date: 2024-04-10 name: Cairo University class: OTHER briefSummary: Retrospective Data Analysis will be performed after the CBCT images are pooled from the computer database.
* Mandibular scans will be collected from planmeca machine, with 0.2-0.4 voxel size to be viewed on Romexis software to do the measurements of mandibular symphysis. Vertical height will be measured from the apices of anterior teeth to inferior border of the mandible from the sagittal and coronal cuts with the orientation lines parallel to the buccal cortical plate. Also, the sagittal cuts will be used to determine the depth of the labial bone, from the apices of anterior teeth the labial cortical plate with the orientation lines parallel to the buccal cortical plate (Safi, Yaser et al.,2021) Whilst horizontal dimension (width) will be measured along the outer surface of the labial cortical bone, which is determined from the inter-foraminal distance. 3D slicer software will be used for this curved measurement on the axial plane, since Romexis software can only do the linear and angular measurements (Lee , Kim et al, 2014).
After collecting the whole data, statistically will be correlated to the age and gender. conditions: Mandibular Symphysis, Block Bone Graft, Mandibular Incisive Canal, and CBCT studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 222 type: ESTIMATED name: CBCT measure: Effect of gender on the mean height of basal bone in the symphysial area measure: Effect of gender on quantity of the bone in symphysial area: *depth of the bone *width of the bone measure: Effect of gender on topography of the bone in symphysial area measure: Effect of age on quantity of the bone in the symphysial area measure: Effect of age on topography of the bone in symphysial area measure: Prevalence of mandibular incisive canal sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357143 id: REMOVE briefTitle: Efficacy of Early Multimodal Physiotherapy in Patients With Reverse Shoulder Prosthesis overallStatus: NOT_YET_RECRUITING date: 2025-01 date: 2026-06 date: 2027-12 date: 2024-04-10 date: 2024-04-10 name: University of Malaga class: OTHER briefSummary: The present study try to evaluate the effectivenness of an early intervention program based on multimodal physiotherapy and focused on therapeutic exercise to improve the results of patients with a reverse shoulder phrostesis. This trial will be a randomized controlled trial with parallel groups, and outcomes variables will include psychometric properties through the use of specific questionnaries, and laboratory variables such as strength with a dynamometer, range of movement with a goniometer, muscle mass with an ultrasound, and kinematic parameters with inertial sensors. This study aims to develop an original intervention program in order to try to establish new protocols in the management of these patients. conditions: Shoulder Fractures conditions: Prosthesis User studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: REMOVE name: CONTROL measure: Functionality measure: Muscle mass measure: Kinematics measure: Strength measure: Range of movement sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06357130 id: CHUBX 2023/75 briefTitle: Gynaecological Care for Transgender People in France in 2024. acronym: GyneTrans overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-04-10 date: 2024-04-29 name: University Hospital, Bordeaux class: OTHER briefSummary: To date, the transgender population, still poorly characterized, tends to increase. The impact of gender-affirming hormone therapy (GAHT) in this population remains poorly understood, and few data are published on the gynecological repercussions of such therapy. A recent literature review by a French team suggests gynecological follow-up procedures for transgender people. conditions: Transgender Management Care studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Questionnaire measure: Percentage of people aware of gynaecological recommendations. measure: Percentage of people aware of cancer risks measure: Percentage of people aware of contraception in transgender male population measure: Percentage of people aware of fertility and the impact of hormone treatments measure: Percentage of people aware of gynaecological repercussions of masculinizing hormone treatment in transgender male population sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hopital Haut-Lévêque city: Pessac zip: 33604 country: France name: Virginie GROUTHIER, MD role: CONTACT phone: 05.57.65.60.78 phoneExt: +33 email: virginie.grouthier@chu-bordeaux.fr name: Clara GUINARD role: CONTACT phone: 05.57.65.60.78 phoneExt: +33 email: clara.guinard@chu-bordeaux.fr lat: 44.81011 lon: -0.64129 hasResults: False